Hanall Biopharma Co (XKRX:009420) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2023)

View and export this data going back to 1989. Start your Free Trial

What is Hanall Biopharma Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Hanall Biopharma Co's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.00.

Hanall Biopharma Co's long-term debt to total assets ratio declined from Dec. 2022 (0.00) to Dec. 2023 (0.00). It may suggest that Hanall Biopharma Co is progressively becoming less dependent on debt to grow their business.

Hanall Biopharma Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Hanall Biopharma Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hanall Biopharma Co LT-Debt-to-Total-Asset Chart

Hanall Biopharma Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

Hanall Biopharma Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Hanall Biopharma Co LT-Debt-to-Total-Asset Calculation

Hanall Biopharma Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	590.309	/	239746.993
	=	0.00

Hanall Biopharma Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	590.309	/	239746.993
	=	0.00

Hanall Biopharma Co (XKRX:009420) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Hanall Biopharma Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Hanall Biopharma Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Hanall Biopharma Co (XKRX:009420) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hanall Biopharma Co Ltd (XKRX:009420) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

N/A

Address

12 Bongeunsa-ro 114-gil, Daewoong Building, 3rd Floor, Gangnam-gu, Seoul, KOR

Website

http://www.hanall.co.kr

Hanall Biopharma Co Ltd is a part of the healthcare sector. It is one of Korea's leading pharmaceutical companies and is focused on drug delivery, biotherapeutics, and new small molecule discovery. The company's scope comprises of ophthalmology, immunology, cardiovascular treatment and dermatology.

Hanall Biopharma Co (XKRX:009420) Headlines

No Headlines